VYST 10-K & 10-Q changes, risk factors and insider trading
Vystar Corp · OTC · Fabricated Rubber Products, Nec · CIK 1308027 · All filings on SEC.gov
At a glance
What changed in the latest 10-K
Risk Factors
Largest changes
Our ability to compete and grow depends in large part on the efforts and talents of our executivesee in full comparisonofficersofficerorand our ability to attract highly qualified employees. We require the key employee(s)to enter into employment agreements, but in the U.S., employees are free to leave an employer at any time without penalties. The loss of our keyemployeesemployee or the inability to hire additional skilled employees as necessary could result in significant disruptions of our business, and the integration of replacement personnel could be time-consuming and expensive and cause us additional disruptions.
Full comparison: every changed paragraph (3)
We source our products from non-exclusive, third-party producers, many of which are located in foreign countries. We depend upon the ability of third-party producers to secure a sufficient supply of raw materials, a skilled workforce, adequately finance the production of goods ordered and maintain sufficient manufacturing and shipping capacity. Tariffs by the U.S. government have impacted future production. We cannot be certain that we will not experience operational difficulties with our manufacturers, such as insufficient quality control, failures to meet production deadlines or increases in manufacturing costs.
Our
ability to compete and grow depends in large part on the efforts and talents of our executive officersofficer orand our ability to attract highly
qualified employees. We require the key
employee(s) to enter into employment agreements, but in the U.S., employees are free to leave an
employer at any time without penalties.
The loss of our key employeesemployee or the inability to hire additional skilled employees as necessary
could result in significant disruptions
of our business, and the integration of replacement personnel could be time-consuming and expensive
and cause us additional disruptions.
Because
of net operating losses we have experienced for federal income tax purposes at December 31, 2024,2025, we had federal net operating loss (“NOL”)
carry-forwards of approximately $39 million ($38 million for 2023) available to offset future taxable income. Our ability to utilize
NOL carry-forwards to reduce
future taxable income may be limited under Section 382 of the Internal Revenue Code if certain ownership
changes in our Company occur
during a rolling three-year period. These ownership changes include purchases of common stock under share
repurchase programs, the offering
of stock by us, the purchase or sale of our stock by 5% shareholders, as defined in the Treasury regulations,
or the issuance or exercise
of rights to acquire our stock. If such ownership changes by 5% shareholders result in aggregate increases
that exceed 50 percentage
points during the three-year period, then Section 382 imposes an annual limitation on the amount of our taxable
income that may be offset
by our NOL carry-forwards or tax credit carry-forwards at the time of ownership change. The limitation may
affect the amount of our deferred
income tax asset and, depending on the limitation, a significant portion of our NOL carry-forwards
or tax credit carry-forwards could
expire before we are able to use them. In such an event, our business, financial condition, results
of operations or cash flows could
be adversely affected. We believe we have not experienced an ownership change under Section 382 of
the Internal Revenue Code as of December
31, 20242025; however, the amount by which our ownership may change in the future could be affected
by purchases and sales of stock by 5%
shareholders and new issuances of stock by us, should we choose to do so.
Management's Discussion & Analysis (MD&A)
Largest changes
“We are monitoring current developments in trade policy and tariff actions by the U.S. government, including imports from China and baseline tariffs on most imports from most other countries. These tariffs could adversely impact our growth and cost of products sold.”see in full comparison
Vystar produces the RxAir product line with a world-class manufacturer and an expert U.S. engineer with a full understanding of the RxAir technology. Vystar sells RxAir residential and commercial units via distributors, online and through retail channels. Vystar has assembled a distribution network for sales ofsee in full comparisonRX400 and RX800, our newest unit tothehealthcareRX400™andFDAmedicalclearedmarkets.Class II Filterless Air Purifier. Vystar also sells theViraTecViraTech replacement cartridgecartridgefor approximately 25,000 units that have been previously sold. TheRX3000,RX3000™ Commercial FDA cleared Class II Air Purifier, our largest unit,hasisbeencurrentlyreengineered and samples of those unitsnot instock. We are not producing more of those at this time.production. We haveengineeredproduced a sample size of theRX300RX800™ FDA cleared Class II Filterless Air Purifier and they are currently in the testing stage. We have asmallerprototypeversionforoftheourRX300,unit andwhichhope towill beinrenamed RX600, and are exploring productionwith that unit in late 2025.options. ThecompanyCompany also hopes to have an even smaller unit designed during 2026 for automobiles and refrigeratorsthat haswith USB charging. Tariffs by the U.S. government may impact future production.
“In May 2025, Vystar announced final testing for the RxAir prototype, integrating the cutting-edge Fluid Energy conversion technology with the Hughes Reactor. This advancement, developed by Dr. Bryan Stone, who serves on Vystar’s board, represents a significant leap in innovation for the Company. We expect testing to be completed by the end of 2026. Due to the fluctuations of tariffs by the U.S. government and cash flows, we expect production in late 2027.”see in full comparison
The Company’s operating expenses consist primarily of share-based compensation andsee in full comparisonsupport costs for management, sales and administrative staff, and forother general and administrative costs, including professional fees related to accounting, finance, and legal services as well as other operating expenses such asadvertisingrent and consulting. The Company’s consolidated operating expenses was$1,587,220$1,092,355 and$1,924,552$1,587,220 for the year ended December 31,20242025 and2023,2024, respectively, for a decrease of$337,332$494,865 or17.5%.31.2%. The decrease in operating expenses was due toreducedaoperationstemporary suspension of consulting fees to Blue Oar Consulting, Inc. (“Blue Oar”), decrease in2024.professional fees consistent with the winding down of litigation matters, and share-based compensation consistent with higher common stock prices.
“Vystar is looking to Fluid Energy as it moves forward in its quest for a cleaner and safer environment. The Company is planning to improve its air purifying by using the ultrasonic technology of Fluid Energy and combining it with its leading UV-C technology. The designs and prototypes are in development. This ultrasonic technology is applied into water products with the same goal. We have a prototype and are evaluating our ability to eradicate hard water pollution that fouls pools, fountains, and pumps. …”see in full comparison
“Net cash provided by financing activities was $176,679 and $61,986 during the year ended December 31, 2025 and 2024, respectively. During 2025, cash was provided from advances from stock subscriptions of $208,636, proceeds of related party advances of $2,000 and proceeds from common stock issuances of $16,364. Cash was used in financing activities during the year for repayments of related party debt of $41,527 and related party advances of $8,794. During 2024, cash of $61,986 was provided by discontinued operations.”see in full comparison
Full comparison: every changed paragraph (23)
The
RxAir product line includes:
Vystar
produces the RxAir product line with a world-class manufacturer and an expert U.S. engineer with a full understanding of the RxAir technology.
Vystar sells RxAir residential and commercial units via distributors, online and through retail channels. Vystar has assembled a distribution
network for sales of RX400 and RX800, our newest unit to the healthcareRX400™ andFDA medicalcleared markets.Class II Filterless Air Purifier. Vystar also sells the ViraTecViraTech replacement cartridge
cartridge for approximately 25,000 units that have been previously sold. The RX3000,RX3000™ Commercial FDA cleared Class II Air Purifier, our largest
unit, hasis beencurrently reengineered and samples
of those unitsnot in stock. We are not producing more of those at this time.production. We have engineeredproduced a sample size of the RX300RX800™ FDA cleared Class II Filterless Air Purifier
and they are currently in the testing stage. We have a smallerprototype versionfor ofthe ourRX300, unit
andwhich hope towill be inrenamed RX600, and are exploring production with that unit in late 2025.
options. The companyCompany also hopes to have an even smaller unit designed during 2026 for
automobiles and refrigerators that haswith USB charging.
Tariffs by the U.S. government may impact future production.
Vytex
researcher Dr. Ranjit Matthan and CMC Global Director John Heath presented at The International Latex Conference which was held virtually
July 20 to 22, 2021 and offered a plenary session entitled “Innovations and Sustainability in Natural Rubber Latex - The New Paradigm.”
The presentation discussed the dramatic effect the COVID-19 pandemic has had on the natural rubber supply chain, and how the industry
is reacting theto new economic circumstances; including strategy and policy shifts in supply chain management and restoring greater geographic
diversification of latex processing and product manufacturing. The R&D association with IRMRA promises quicker laboratory and field-based
testing and evaluations downstream. At Vystar, the recalibrated sustainability programme (FSC, nitrosamines & ammonia free, ultralow
proteins, no SVHC and green carbon neutrality) emphasize certifications with Corrie MacColl market reach facilitating faster rollouts.
Nontraditional/non Hevea brasiliensis based production efforts are likely to continue to face new penetration and high cost-benefit
acceptance challenges in this decade. A PDF of the full presentation is available on vytex.com.
In July 2025, the Company unveiled a newly redesigned website, www.vytex.com, as part of a comprehensive brand refresh aimed at improving customer interaction and enhancing digital presence. This initiative aligns with our strategy to provide a more engaging and user-friendly experience for our customers.
About FEC
Vystar is looking to Fluid Energy as it moves forward in its quest for a cleaner and safer environment. The Company is planning to improve its air purifying by using the ultrasonic technology of Fluid Energy and combining it with its leading UV-C technology. The designs and prototypes are in development. This ultrasonic technology is applied into water products with the same goal. We have a prototype and are evaluating our ability to eradicate hard water pollution that fouls pools, fountains, and pumps. By the end of the year, we expect to run a trial on FEC/Hughes devices for hard water abatement and dialysis membrane efficiency. These products will move us toward living more safely and cleanly in our environment.
In May 2025, Vystar announced final testing for the RxAir prototype, integrating the cutting-edge Fluid Energy conversion technology with the Hughes Reactor. This advancement, developed by Dr. Bryan Stone, who serves on Vystar’s board, represents a significant leap in innovation for the Company. We expect testing to be completed by the end of 2026. Due to the fluctuations of tariffs by the U.S. government and cash flows, we expect production in late 2027.
Other Matters
We are monitoring current developments in trade policy and tariff actions by the U.S. government, including imports from China and baseline tariffs on most imports from most other countries. These tariffs could adversely impact our growth and cost of products sold.
Leases
The
Company has adopted and implemented ASC 842, Leases, where Rotmans recognized right-of use assets and lease liabilities. For leases in
which the acquiree is a lessee, the Company measured the lease liability at the present value of the remaining lease payments, as if
the acquired lease were a new lease at the acquisition date. The Company measured the right-of-use asset at the same amount as the lease
liability as adjusted to reflect favorable and unfavorable terms of the lease when compared with market terms.
Consolidated
revenues for the year ended December 31, 20242025 and 20232024 were $135,969$54,821 and $525,883,$135,969, respectively, for a decrease of $389,914$81,148 or 74.1%.59.7%. The
Revenues from operationsdecrease in 2023revenues was increaseddue byin approximately $401,000 duepart to decreasedreduced allowancessales to a former major customer and shippinga tospecial distributors.bulk Withoutsale of Vytex products in 2024. The
theseCompany modifications,will revenuesaggressively forreview 2024its pricing and 2023sales wouldstrategies bein consistent year over year.2026.
Consolidated
gross profit for the year ended December 31, 20242025 and 20232024 was $69,641$31,815 and $384,583,$69,641, respectively, for a decrease of $314,942$37,826 or 81.9%.54.3%.
Consolidated cost of revenue for year ended December 31, 20242025 and 20232024 was $66,328$23,006 and $141,300,$66,328, respectively, a decrease of $74,972$43,322 or
or 53.1%.65.3%. The decrease in gross profit and decrease in cost of revenue was primarily due to inventorydecreased sales and salesincreased allowancechannel modifications
in 2023. Our allowances are conservatively stated for our inventory valuation.costs.
The
Company’s operating expenses consist primarily of share-based compensation and support costs for management, sales and administrative staff,
and for other general and administrative costs, including
professional fees related to accounting, finance, and legal services as well
as other operating expenses such as advertisingrent and consulting.
The Company’s consolidated operating expenses was $1,587,220$1,092,355 and
$1,924,552 $1,587,220 for the year ended December 31, 20242025 and 2023,2024, respectively,
for a decrease of $337,332$494,865 or 17.5%.31.2%. The decrease in operating
expenses was due to reduceda operationstemporary suspension of consulting fees to Blue
Oar Consulting, Inc. (“Blue Oar”), decrease in 2024.professional fees consistent with the winding down of litigation matters,
and share-based compensation consistent with higher common stock prices.
Other
income (expense), net for the year ended December 31, 20242025 and 20232024 was $(154,488470,854) and $543,252,$(154,488), respectively, for an decreaseincrease of $697,740$316,366
or 128.4%.204.8%. DecreasesThe increase in 2024other includedexpenses is primarily due to increases in interest expense of $156,818 and a gainchange in net loss on settlement
of liabilities of $77,560 as compared to $596,670 in 2023, an increase in
interest expense of $194,170. which was reduced by other income of $15,540 in 2024$144,008.
Income
(loss) from discontinued operations for the year ended December 31, 20242025 and 20232024 was $4,192,379$(456) and $(7,322,678),$4,192,379, respectively, for a decrease
an increase of $11,515,057$4,192,835 or 157.3%.100%. The increasedecrease was attributable to the derecognition of Rotmans facility lease inand 2024 as compared
tothe winding down of operations
in 2023.2024.
Net
income (loss) for the year ended December 31, 20242025 and 20232024 was $2,520,312$(1,531,850) and $(8,319,395),$2,520,312, respectively. Net income in 2024 includes
income from discontinued operations of $4,192,379 compared to a loss from discontinued operations of $7,322,678 in 2023.$4,192,379.
The
Company’s financial statements are prepared using the accrual method of accounting in accordance with accounting principles generally
accepted in the United States of America and have been prepared on a going concern basis, which contemplates the realization of assets
and the settlement of liabilities in the normal course of business. However, we have incurred significant losses and experienced negative
cash flow since inception. At December 31, 2024,2025, the Company had cash of $7,712$4,454 and a deficit in working capital of $5,432,726.$6,614,169. For the
year ended December 31, 2025, the Company had a net loss of $1,531,850 and an accumulated deficit of $61,384,883. For the year ended
December 31, 2024, the Company had a net income of $2,520,312 and an accumulated deficit of $59,853,225. For the year ended
December 31, 2023, the Company had a net loss of $8,319,395 and the accumulated deficit amounted to $60,612,738.$59,853,225. We use working capital
to finance our ongoing operations, and since those operations do not currently cover all of our operating costs, managing working capital
is essential to our Company’s future success. Because of this history of losses and financial condition, there is substantial doubt
about the Company’s ability to continue as a going concern.
The
Company had no cash flows provided by investing activities during the year ended December 31, 2025. The Company had cash flows provided
by investing activities from discontinued operations of $1,000 and $592,483 during the year ended December
31, 2024 and 2023, respectively, for sales of property and equipment.
Net cash provided by financing activities was $176,679 and $61,986 during the year ended December 31, 2025 and 2024, respectively. During 2025, cash was provided from advances from stock subscriptions of $208,636, proceeds of related party advances of $2,000 and proceeds from common stock issuances of $16,364. Cash was used in financing activities during the year for repayments of related party debt of $41,527 and related party advances of $8,794. During 2024, cash of $61,986 was provided by discontinued operations.
Net
cash provided by financing activities was $61,986 during the year ended December 31, 2024, as compared to cash used in $235,066 during
the year ended December 31, 2023. During 2024, cash of $61,986 was provided by discontinued operations. During 2023, cash was provided
from the proceeds of related party advances of $152,434 and used in discontinued operations of $387,500.
During
the year ended December 31, 2024,2025, the Company expensed approximately $440,000$375,000 related to this employment agreement. Vystar issued 1,300,000
shares of common stock on December 23, 2024 for share-based compensation totaling $76,112. As of December 31, 2024,
2025, the Company had a
stock subscription payable balance of $363,853$738,684 or approximately 24,475,00028,072,000 shares of common stock to Ms. Rotman.
Blue
Oar Consulting, Inc. (“Blue Oar”) provides business consulting services to the Company. This entity is owned by Gregory Rotman,
who is the sisterbrother of the Company’s
CEO, Jamie Rotman. Blue Oar provides business consulting services to the Company. In exchange
for such services, the Company has entered into a consulting agreement with the related party entity.
Per the consulting agreement, Blue
Oar is to be paid $15,000 per month in cash for expenses, and $12,500 per month to be paid in shares
based on a 20-day average at a 50%
discount to market. The Company and Blue Oar mutually agreed to temporarily suspend the monthly payment
for expenses beginning in January 2025. During the year ended December 31, 2024,2025, the Company expensed approximately $633,000$312,000 related
to the consulting agreement.
Vystar issued 1,509,6424,036,812 shares of common stock onduring December 23, 20242025 for prior accrued share-based compensation totaling $632,263.
$63,806. As
of December 31, 2024,2025, the Company had a stock subscription payable balance of $851,022,$1,099,573, or approximately 110,407,000109,368,000 shares
to be issued
in the future and $405,000 of consulting expenses in accounts payable to this entity.
What changed in the latest 10-Q
Risk Factors
We could not find a separate Risk Factors item in the latest 10-Q. Some companies leave it out of quarterly reports; see the annual 10-K risk factors and the original filing. Open the filing on SEC.gov.
Management's Discussion & Analysis (MD&A)
Not available: the section could not be located automatically in one of the filings (non-standard layout or incorporated by reference). See the original filing. Open the filing on SEC.gov.
VYST insider buying and selling (Form 4)
Since 2026-04-11, insiders reported open-market purchases in 0 Form 4 filings and open-market sales in 0 filings. Totals add up every open-market (code P and S) line in those filings, using the prices reported in the filings. Awards, option exercises, tax withholding and gifts are listed below but not counted.
No Form 4 stock transactions in this period.
Well-known investors holding VYST (13F)
None of the 59 investors we track reported a position in their latest 13F.